Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04998747
Recruitment Status : Not yet recruiting
First Posted : August 10, 2021
Last Update Posted : October 20, 2021
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
A study to evaluate the safety and tolerability of subcutaneous (SC) AMG 701 in participants with relapsed or refractory multiple myeloma (RRMM) to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D)

Condition or disease Intervention/treatment Phase
Relapsed/Refractory Multiple Myeloma Drug: AMG 701 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 47 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)
Estimated Study Start Date : December 6, 2021
Estimated Primary Completion Date : June 4, 2024
Estimated Study Completion Date : December 10, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: AMG 701: dose exploration
Cohorts of 3 to 6 participants each will be administered AMG 701 at different doses to determine the RP2D based on occurence of dose-limiting toxicities (DLTs) and on emerging safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy data.
Drug: AMG 701
AMG 701 will be administered as SC or intravenous injection.

Experimental: AMG 701: dose expansion
Participants will be administered AMG 701 at the RP2D determined from dose exploration stage to further assess the safety, PK, PD, and efficacy of the selected dose.
Drug: AMG 701
AMG 701 will be administered as SC injection.




Primary Outcome Measures :
  1. Number of participants who experience dose-limiting toxicities (DLTs) [ Time Frame: 28 days ]
  2. Number of participants who experience one or more treatment-emergent adverse events (TEAEs) [ Time Frame: up to approximately 9 months ]
  3. Number of participants who experience one or more treatment-related TEAEs [ Time Frame: up to approximately 9 months ]
  4. Number of participants with abnormal changes in vital signs [ Time Frame: up to approximately 9 months ]
  5. Number of participants with abnormal changes in electrocardiograms (ECGs) findings [ Time Frame: up to approximately 9 months ]
  6. Number of participants with abnormal changes in clinical laboratory tests [ Time Frame: up to approximately 9 months ]

Secondary Outcome Measures :
  1. Maximum serum concentration (Cmax) of AMG 701 [ Time Frame: up to approximately 8 months ]
  2. Time to maximum concentration (Tmax) of AMG 701 [ Time Frame: up to approximately 8 months ]
  3. Area under the concentration-time curve (AUC) of AMG 701 [ Time Frame: up to approximately 8 months ]
  4. Minimum concentration over the dosing interval (Ctrough) of AMG 701 [ Time Frame: up to approximately 8 months ]
  5. Incidence of anti-AMG 701 antibody formation [ Time Frame: up to approximately 9 months ]
  6. Overall response (OR) [ Time Frame: up to approximately 8 months ]
  7. Best overall response (BOR) [ Time Frame: up to approximately 8 months ]
  8. Time to response [ Time Frame: up to approximately 8 months ]
  9. Duration of response (DOR) [ Time Frame: up to approximately 8 months ]
  10. Progression-free survival (PFS) [ Time Frame: up to approximately 3 years ]
  11. Overall survival (OS) [ Time Frame: up to approximately 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant has provided informed consent prior to initiation of any study specific activities/procedures.
  • Age 18 years or older at the time of signing the informed consent.
  • Relapsed or relapsed and refractory multiple myeloma according to International Myeloma Working Group (IMWG) criteria.
  • Participants must have received ≥ 3 prior therapies that must include all approved and available therapies deemed eligible by the investigator, including at a minimum, a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and a CD38-directed antibody. Note: Participants may have received prior treatment targeting BCMA that is not AMG 701.
  • Participants must have measurable disease, defined by 1 or more of the following at time of screening :

    • A serum M protein ≥ 0.5 g/dL measured by serum protein electrophoresis (SPEP)
    • Urinary M protein excretion ≥ 200 mg/24 hours
    • Involved serum free light chain (sFLC) measurement ≥ 10 mg/dL, provided that SFLC ratio is abnormal as per IMWG response criteria
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
  • Life expectancy of at least 3 months as per investigator's judgment at time of screening
  • Hematological function without transfusion support as follows:

    • Absolute neutrophil count ≥ 1.0 x 10^9/L (without growth factor support)
    • Platelet count ≥ 50 x 10^9/L (without transfusions within 7 days from screening assessment)
    • Hemoglobin ≥ 8.0 g/dL (transfusions permitted no later than 48 hours before screening)
  • Renal function as follows:

Calculated or measured creatinine clearance ≥ 30 mL/min using:

  • The Cockcroft-Gault equation OR
  • Via 24-hour urine collection with plasma and urine creatinine concentrations

    • Hepatic function as follows:
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)
  • Total bilirubin (TBIL) < 1.5 x ULN (unless considered due to Gilbert's syndrome)

    • Cardiac function as follows:
  • Left ventricular ejection fraction ≥ 50% as assessed by transthoracic echocardiogram (TTE) or multigated acquisition (MUGA) scan.

    • Serum sodium, potassium, phosphorus, calcium, and magnesium must be within normal range or if outside normal range must have resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 1 within 7 days of day 1. Participants not meeting these inclusion criteria may be treated with replacement therapy and re-screened up to 2 times at the discretion of the investigator.
    • Participants with prior COVID-19 infection or history of cardiovascular disease including coronary artery disease, significant valvular disease, cardiac arrhythmia, cardiomyopathy, or history of cardiac toxicity with prior therapy must have a cardiology consultation during screening with a clinical management plan during cytokine release syndrome (CRS) prior to cycle 1 day 1 therapy.
    • Participants with a history of COVID-19 infection must be discussed with the medical monitor prior to enrollment. Participants with a history of COVID-19 infection must have a negative quantitative polymerase chain reaction (PCR) test prior to enrollment.

Exclusion Criteria:

  • Known central nervous system involvement by multiple myeloma.
  • Recent history of primary plasma cell leukemia (within last 6 months prior to enrollment) or evidence of primary or secondary plasma cell leukemia at the time of screening.
  • Waldenström macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes), or amyloidosis (participants with multiple myeloma with asymptomatic amyloid plaques found on biopsy would be eligible if all other criteria are met).
  • History or evidence of any of the following cardiovascular disorders:

    • Active congestive heart failure (New York Heart Association Class III to IV)
    • Symptomatic ischemia
    • Uncontrolled arrhythmias
    • Screening ECG with corrected QT interval (QTc) of > 470 msec
    • Myocardial infarction within 12 months prior to study day 1
  • History of malignancy other than multiple myeloma within the past 3 years with the following exceptions:

    • Malignancy treated with curative intent and with no known active disease present for at least 1 year before enrollment and felt to be at low risk for recurrence by the treating physician.
    • Adequately treated cervical carcinoma in situ without evidence of disease.
    • Breast ductal carcinoma in situ with full surgical resection (ie, negative margins) and without evidence of disease
    • Prostate cancer with a Gleason score < 7 with undetectable prostate specific antigen over 12 months
    • Treated medullary or papillary thyroid cancer
    • Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ
    • Similar neoplastic conditions with an expectation of > 95% 5-year disease-free survival
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  • Clinically uncontrolled chronic or ongoing bacterial, fungal, viral, or other infectious disease at study day 1 or within 14 days before study day 1.
  • Positive result for human immunodeficiency virus (HIV).
  • Active hepatitis B and C based on the following results:

    • Positive for hepatitis B surface antigen (HepBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B)
    • Negative HepBsAg and positive for hepatitis B core antibody: Either a positive hepatitis B surface antibody or a negative hepatitis B virus DNA by PCR result is necessary for enrollment
    • Positive hepatitis C virus antibody: Negative hepatitis C virus RNA by PCR result is necessary for enrollment
  • Unresolved toxicities from prior anticancer therapy, defined as not having resolved to CTCAE version 5.0 grade 1 or to levels dictated in the eligibility criteria with the exception of grade 2 peripheral neuropathy, alopecia or toxicities from prior anticancer therapy that are considered irreversible (defined as having been present and stable for > 4 weeks) which may be allowed if they are not otherwise described in the exclusion criteria and there is agreement to allow by both the investigator and Amgen medical monitor.
  • Known hypersensitivity to immunoglobulins.
  • Current autoimmune disease that is not well-controlled.
  • Past history or current significant inflammatory neuropathy such as Guillain-Barré syndrome, Chronic inflammatory demyelinating polyradiculoneuropathy, or Multifocal motor neuropathy.
  • Previously received an allogeneic stem cell transplant and the occurrence of 1 or more of the following:

    • Received the transplant within 6 months prior to study day 1
    • Received immunosuppressive therapy within the last 3 months prior to study day 1
    • Any active acute graft versus host disease (GvHD) requiring systemic therapy within the last 4 weeks prior to start of study treatment
    • Any systemic therapy against GvHD within 4 weeks prior to start of investigational product treatment
  • Autologous stem cell transplantation less than 90 days prior to study day 1.
  • Last non-antibody anticancer treatment (chemotherapy, IMiD, PI, molecular targeted therapy) < 2 weeks and last anticancer therapeutic antibody < 4 weeks prior to study day 1.
  • Lymphodepleting chemotherapy (eg, fludarabine, cyclophosphamide, or anti-CD52 antibody in association with chimeric antigen-receptor T-cell therapy) < 3 months prior to study day 1.
  • Radiation therapy to multiple anatomic sites within 28 days prior to study day 1.
  • Focal radiotherapy within 14 days prior to study day 1.
  • Treatment with systemic immune modulators including, but not limited to, non-topical systemic corticosteroids (unless the dose is less ≤ 10 mg/day prednisone or equivalent), cyclosporine, and tacrolimus within 2 weeks before study day 1.
  • Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded.
  • Administration of bone preserving therapies (including bisphosphonates) within 14 days of cycle 1 day 1.
  • Major surgery defined as surgery requiring general anesthesia with endotracheal intubation within 28 days prior to study day 1, unless discussed with and eligibility approved by Amgen medical monitor.
  • Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 75 days after the last dose of AMG 701.
  • Female participants who are breastfeeding or who plan to breastfeed while on study through 75 days after the last dose of AMG 701.
  • Female participants planning to become pregnant while on study through 75 days after the last dose of AMG 701.
  • Female participants with a positive pregnancy test.
  • Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 135 days after the last dose of AMG 701.
  • Male participants unwilling to abstain from donating sperm during treatment and for an additional 135 days after the last dose of AMG 701.
  • Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the participant and investigator's knowledge.
  • History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04998747


Contacts
Layout table for location contacts
Contact: Amgen Call Center 866-572-6436 medinfo@amgen.com

Sponsors and Collaborators
Amgen
Investigators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT04998747    
Other Study ID Numbers: 20200446
First Posted: August 10, 2021    Key Record Dates
Last Update Posted: October 20, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
URL: http://www.amgen.com/datasharing

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Amgen:
AMG 701
Relapsed/Refractory Multiple Myeloma
B-cell maturation antigen (BCMA)
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases